医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

HeartFlow FFRct Analysis Receives Regulatory Approval in Japan

2016年11月17日 PM09:00
このエントリーをはてなブックマークに追加


 

REDWOOD CITY, Calif.

HeartFlow, Inc. has announced the approval of its HeartFlow® FFRct Analysis by the Japanese Ministry of Health, Labour and Welfare (MHLW). The HeartFlow FFRct Analysis is the only non-invasive technology to deliver insights on both the extent of a coronary blockage and any impact the blockage has on blood flow to the heart, aiding clinicians in selecting an appropriate treatment.

Also commercially available in the United States, Europe and Canada, the innovative technology has been proven to reduce the need for invasive and costly procedures to diagnose patients suspected of having coronary artery disease. It has the potential to positively impact a significant patient population in Japan, where heart disease is the second leading cause of death and coronary artery disease accounts for approximately half of these deaths.1

“The MHLW’s approval of the HeartFlow FFRct Analysis is another important milestone for HeartFlow and will give physicians in Japan a new tool to determine the optimal treatment for patients with cardiovascular disease,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “With our commercial release in Japan, we expand our ability to help more clinicians diagnose cardiovascular disease non-invasively while reducing unnecessary invasive catheterizations and saving costs.”

The HeartFlow FFRct Analysis is a web-based platform that aids clinicians in diagnosing coronary artery disease, and provides personalized, actionable information to physicians to manage each patient. The technology solves millions of complex equations simulating blood flow in the coronary arteries to provide mathematically computed fractional flow reserve (FFRct) values. The result is a personalized color-coded model of the patient’s coronary arteries that aids physicians in determining, vessel-by-vessel, if sufficient blood is reaching the heart.

“We are very pleased that the MHLW has approved the novel HeartFlow FFRct Analysis,” said Takashi Akasaka, M.D., Ph.D., Professor of Medicine, Department of Cardiovascular Medicine, Wakayama Medical University. “Having used the technology as part of clinical studies at our facility, we believe it has the potential to profoundly impact the way we care for cardiovascular patients in Japan.”

About HeartFlow, Inc.

HeartFlow, Inc. is a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow FFRct Analysis is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy and physiology. The novel solution, which produces a model of the patient’s coronary arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience and reduce the cost of care. The HeartFlow Analysis is commercially available in the United States, Canada, Europe and Japan. For more information visit www.heartflow.com.

1 Iso H. Changes in Coronary Heart Disease Risk Among Japanese. Circulation. 2008;118:2725-2729

View source version on businesswire.com: http://www.businesswire.com/news/home/20161117005294/en/

CONTACT

HeartFlow, Inc.
Chris B. Ernst, 415-710-9445
cernst@heartflow.com
or
Nobles
Global Communications
Diana Soltesz, 818-618-5634
diana@noblesgc.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease